Beruflich Dokumente
Kultur Dokumente
Myasthenia Gravis
A 28 year-old woman presents with a six-week history of fluctuating eye droopiness and
intermittent double vision. For the past 2 weeks she has been experiencing difficulty
swallowing and her speech has become slurred in several occasions. She also reports
fatigue in her arms and legs and some shortness of breath but denies any numbness or
pain. Physical examination reveals right fatigable ptosis, diplopia on left lateral gaze,
nasal dysarthria, a flat smile and weakness of neck flexion and bilateral deltoids, biceps,
finger extensors, hip flexion and foot dorsiflexion. . How should her case be managed?
weakness. Symptoms usually begin in one of three muscles groups: eyes (ptosis and
Symptoms are usually more pronounced in the evening. {{2 Drachman,D B. 1994; }}
Epidemiology
Numerous studies have looked at the incidence and prevalence of MG over the
2000; }} whereas an earlier study showed a higher prevalence at about 14 per 100,000
persons.{{5 Phillips,L.H.,2nd 1996; }} Most recently, Philips showed that there are
around 60,000 MG patients in the US. {{3 Phillips,L.H. 2004; }} There seems to be an
increase in incidence, probably due to increasing efficiency of diagnosis. There is a
female preponderance for cases with onset before age 40, consistent with many
autoimmune disorders. After age 40 however, the occurrence equalizes between the
sexes.
Etiology/Pathophysiology
manifested most commonly by the presence of antibodies against the AChR. {{6 Ricny,J.
2002; }} {{28 Vincent,A. 2003; }} A substantial amount of evidence indicates that these
immunoglobulins play a central role in the pathogenesis of MG. Studies have shown that
MG can be passively transferred to mammals with serum from affected patients {{7
Toyka,K.V. 1975; }} Studies have also shown that plasmapheresis, which reduces the
While some of the symptoms can be explained by the passive blocking of the
AChR {{10 Bufler,J. 1998; }} there is actually a more complicated cascade. The
observation that MG patients have lower numbers of muscle AChR suggests that there is
that most of the damage comes from the activation of complement and subsequent
1982; }}
Humoral immunity however, does not account for all the pathophysiology and
defects in cell mediated immunity have also been shown. The chief observation that
suggests that defective cell mediated immunity plays a role MG is the observation of
helper cells which subsequently activate auto-reactive B cells that produce antibodies
directed against the AChR. {{32 Yi,Q. 1993; }} This is buttressed by the fact that there is
an association with the MHC II locus and a correlation with other autoimmune diseases.
Although the exact mechanism of how and why aberrant T cells get activated
remains unknown, a prominent theory suggests that a viral infection of the myoid cells in
the thymus is the initiating event. The CD8 Tc cells then attack these myoid cells which
subsequently puts the skeletal muscles AChR in jeopardy of autoimmune attack. {{1
While the pathogenesis of MG is fairly well characterized, some gaps exist. For
instance, symptoms of MG do not always correlate with antibody levels, and seronegative
cases have also been documented (although recent evidence suggests that a proportion of
seronegative cases have the anti-musk antibodies present). {{28 Vincent,A. 2003; }}
Nonetheless, the autoimmune attack on the AChR’s then produces the symptoms
characteristic of MG. In normal muscles there are more ACh receptors than needed
which provides a safety factor for muscle contraction. The destruction of ACh receptors
removes this safety factor. More ACh release is now required for normal contraction.
stimulation.
weakness. The first symptom in many individuals is either diplopia (double vision due to
should be excluded before making this diagnosis. {{30 Grob,D. 1987; }} A careful
extraocular muscles. Other parts of the history and physical may help to rule out MS,
The pupillary light reflex is generally intact ruling out a focal CN III palsy.
Ophthalmoplegia is usually fluctuating and not definitively localized to the III, IV, and VI
cranial nerves. Fatigable ptosis, elicited by asking the patient to maintain sustained up-
gaze, (curtain sign) is perhaps one of the most useful features on exam.
cranial nerve motor nuclei originating in the medulla (face and oropharynx). This
uncommon for MG to present solely with limb and neck musculature involvement
emotional stresses, medications and pregnancy are all possible triggers. Nonetheless,
spontaneous exacerbations and crisis can occur without evident stressors as well. A
A minority of patients with severe dysphagia are at risk for malnutrition. These
patients often also have muscular atrophy. The atrophy however, is not a manifestation of
lower motor neuron disease but more a marker of malnutrition as verified by the diffuse
nature of the atrophy and the absence fasciculations. Occasionally some patients may
subset is termed purely ocular myasthenia and such patients have lower titers of anti-
The rest of the neurological exam should be normal. Since the sensory system is
unaffected, both protopathic and epicritic sensations should be intact. Generally reflexes
are preserved, even in the weak muscles, although with long standing untreated MG there
Neuromuscular Junction Transmission. Year Two case Seminars. Block 2-The Weak
patient. 2007)
MG is the Tensilon (Edrophonium) test. {{24 Daroff,R.B. 1986; }} Injection of this short
test is not without hazard. Since ACh is also utilized by the parasympathetic system,
some patients may develop bradyarrythmias (treated with Atropine). As this is more
likely in older people, EKG’s are recommended in this group. It is better to avoid this
test in asthmatics and people prone to arrhythmias. An alternative to the tensilon test is
the repetitive nerve stimulation study, a nerve innervating a weak muscle is stimulated at
3 Hz. A positive MG tests will show more than 10% decrement in the compound muscle
action potential (CMAP) amplitude. This study has a relatively high sensitivity when
multiple muscles are used though other diseases such as myotonic myopathy, periodic
The second study is single fiber EMG. In MG, the characteristic findings include
and increase in jitter and blocking. While this is the most sensitive test, it is also
expensive and time consuming and hence rarely performed. The test is also positive in
Lab studies including hematologic, CSF, urinalysis are usually normal. Detection
of antibodies against the acetylcholine receptor (anti-AChR) is very specific for the
realize however that antibody titers do not always correlate with clinical symptoms.
Imaging
thymoma imaging with MRI or CT to rule out a thymoma and to stratify patients for
Differential Diagnosis
After ruling out stroke, MS, INO, toxins (organophosphates, cholinergics), and
thyroid abnormalities, the differential for myasthenia is fairly limited. The most common
Unlike MG however the weakness associated with LEMS improves with exercise.
LEMS has an increased prevalence in older males, and is frequently associated with
malignancy. EMG studies will rule out myopathies and neuropathies. Bulbar ALS can
also mimic myasthenia as it can present with fatigable dysarthria worse at the end of the
day. Moreover there have also been cases in the literature of ALS with ophthalmoplegia.
{{43 Palmowski,A. 1995; }} Since ALS is a serious life threatening diagnosis this has to
Treatment
treatment to limit disease progression. The most frequent symptomatic treatment is the
predominantly acute treatments, targeting the immune system. The treatment modalities
preparations exist. As with edrophonium, these drugs can have muscarinic side effects
such as abdominal cramps, diarrhea and increased salivation. Regimens can be designed
to achieve peak concentrations to coincide with the activity that the patient is most
restricted in. Studies comparing efficacies of the various drugs in this class are lacking.
Despite their relative success, anticholinesterase drugs are not a panacea. Almost
universally, some symptoms persist, side effects occur, underlying pathogenesis continues
Thymectomy
Sempowski,G. 2001; }} Thymectomy has been one of the greatest successes in the
treatment of MG, and observational studies suggest an efficacy of around 80% in patients
patients with generalized MG. The beneficial effects of thymectomy are delayed and
only become clinically evident after months. The two main surgical methods for
performing a thymectomy are transcervical and transthoracic. The removal of the entire
gland is associated with a better outcome. Pre and post-operative plasmapheresis, IVIG
and corticosteroids are routinely used to prophylax against crisis. {{35 Gronseth,G.S.
2000; }}
Plasmapheresis/Plasma exchange
present in MG. It is primarily used for treating exacerbations and providing rapid relief
IVIG therapy
exact mechanism for the therapeutic effect seen by IVIG remains uncertain, numerous
hypotheses have been suggested. The mechanism which enjoys the most popular support
is the supposition that amongst the pooled IgG are some anti-idiotypic antibodies which
react with and remove from the circulation the autoimmune humoral components
responsible for the symptoms of MG. Other mechanisms proposed include the
hypothesis that the pooled IgG inhibits complement mediated lysis and that it modulates
the immune response. IVIG however is not entirely benign. Side effects include
headache, aseptic meningitis, muscle pains, rashes, etc. plasmapheresis and IVIG are
swift, ephemeral, and costly. {{38 Dalakas,M.C. 2004; }} {{39 Illa,I. 2005; }}
Corticosteroids
Like in other autoimmune disorders, corticosteroids are generally required to halt
disease progression. Apart from immune suppression, corticosteroids may also have an
of prednisone has been correlated with a transient worsening of symptoms, a low dose is
used initially and then gradually increased to around 1mg/kg. Therapeutic effects are
usually rapid. Because of the side effects of corticosteroids (osteoporosis, increased risk
of infection, etc) gradual tapers have to be instituted. Alternate day regimens along with
Schneider-Gold,C. 2005; }}
Other Immunosuppresives
These medications are usually reserved for people who do not show a response to
Other Issues:
For the most part, a crisis is managed by maintaining vital functions. After
tracheal intubation, cholinergic drugs are usually stopped due to the potential for
MG will complicate the pregnancy. Many MG therapies are known teratogens, and drugs
and therapies have to be adjusted to minimize harm to the fetus and maximize efficacy
for the mother. It is highly recommended that a woman planning a pregnancy should
consult with her neurologist before the pregnancy. {{16 Ciafaloni,E. 2004;17
Areas of Uncertainty
Despite the tremendous strides made in the diagnosis and treatment of MG, there
remain many areas of uncertainty. Efforts are underway to better understand and
immunologic mechanisms). This will aid in designing targeted therapeutic regimens. {{8
Steinman,L. 1990; }} There are an increasing number of trials looking at the role of
alternative immunosuppressives with fewer side effects in MG. One such drug that has
Guidelines
Since MG can present in a wide variety of ways, and in a very diverse patient
majority of cases, diagnosis is easily ascertained with Tensilon testing and the history and
physical. Electrodiagnostic testing and AChR Ab titers confirm the diagnosis. Most of
the time treatment has to be individually tailored to suit the specific needs of individual
patients. Evidence based reviews for particular therapeutic regimens have been
conducted and are widely available. The evidence based review for thymectomy for
instance indicates that thymectomy is recommended for most people with generalized
In older patients where the risks of surgery may outweigh the benefits, thymectomy
Ina all patients who present with such symptoms, a thorough history and physical
should be performed. In this particular patient, the history and physical strongly suggest
MG. Since she is young and has low risk factors for bradyarrhythmias, Tensilon testing
would be indicated. The diagnosis can be confirmed by testing for AChR Ab. If these
Since she has moderate bulbar symptoms, a course of PLEX or IVIG would be
useful to stabilize her. This would also prepare her for chronic immunosuppression using
protocol is to start with 20mg po qd and titrate upwards gradually till around 2mg/kg qod.
This dose is maintained for a few months then tapered. A long acting anticholinesterase
should be continued as long as symptoms remain. Once the disease goes into remission
adjunct with steroid sparing effects. Due to the potential for liver toxicity, blood counts
and liver enzymes need to be monitored. While not proven to be teratogenic, its use is
discouraged during pregnancy. Cyclophosphamide and cyclosporine are fairly toxic and
hence reserved for refractory patients. Once again due to the risk for spontaneous
abortion, the use of cyclosporine is discouraged in pregnancy. Anew drug showing great
promise is MMF. Since it is relatively new, its effects during pregnancy remain
not be performed when pregnant. Since pregnancy can exacerbate MG, a considerable
amount of counseling will need to be done to inform the patient of the risks to both the
fetus and the mother of both some of the therapies, and of untreated MG.
While managing an MG patient can be difficult, it s often touted as one of the great
References
1. Bufler J, Pitz R, Czep M, Wick M, Franke C. Purified IgG from seropositive and
seronegative patients with mysasthenia gravis reversibly blocks currents through
nicotinic acetylcholine receptor channels. Ann Neurol 1998;43:458-64.
2. Castleman B. The pathology of the thymus gland in myasthenia gravis. Ann N Y Acad
Sci 1966;135:496-505.
3. Ciafaloni E. Mycophenolate mofetil and myasthenia gravis. Lupus 2005;14:s46-9.
4. Ciafaloni E, Massey JM. Myasthenia gravis and pregnancy. Neurol Clin 2004;22:771-
82.
5. Ciafaloni E, Massey JM. The management of myasthenia gravis in pregnancy. Semin
Neurol 2004;24:95-100.
7. Ciafaloni E, Nikhar NK, Massey JM, Sanders DB. Retrospective analysis of the use of
cyclosporine in myasthenia gravis. Neurology 2000;55:448-50.
9. Clark WF, Rock GA, Buskard N, et al. Therapeutic plasma exchange: an update from
the Canadian Apheresis Group.see comment. Ann Intern Med 1999;131:453-62.
10. Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune
neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther
2004;102:177-93.
11. Daroff RB. The office Tensilon test for ocular myasthenia gravis. Arch Neurol
1986;43:843-4.
12. Dau PC, Lindstrom JM, Cassel CK, Denys EH, Shev EE, Spitler LE. Plasmapheresis
and immunosuppressive drug therapy in myasthenia gravis. N Engl J Med
1977;297:1134-40.
13. Drachman DB. Myasthenia gravis. The New England journal of medicine
1994;330:1797.
14. Drachman DB, Adams RN, Josifek LF, Self SG. Functional activities of
autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis. N
Engl J Med 1982;307:769-75.
15. Golnik KC, Pena R, Lee AG, Eggenberger ER. An ice test for the diagnosis of
myasthenia gravis.see comment. Ophthalmology 1999;106:1282-6.
16. Grob D, Arsura EL, Brunner NG, Namba T. The course of myasthenia gravis and
therapies affecting outcome. Ann N Y Acad Sci 1987;505:472-99.
17. Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune
myasthenia gravis (an evidence-based review): report of the Quality Standards
Subcommittee of the American Academy of Neurology.see comment. Neurology
2000;55:7-15.
18. Illa I. IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and
inflammatory myopathies: current status. J Neurol 2005;252:14-8.
19. Kao I, Drachman DB. Thymic muscle cells bear acetylcholine receptors: possible
relation to myasthenia gravis. Science 1977;195:74-5.
21. Mayer SA, Thomas CE. Therapy of myasthenic crisis.comment. Crit Care Med
1998;26:1136-7.
22. McConville J, Farrugia ME, Beeson D, et al. Detection and characterization of MuSK
antibodies in seronegative myasthenia gravis. Ann Neurol 2004;55:580-4.
23. Meriggioli MN, Ciafaloni E, Al-Hayk KA, et al. Mycophenolate mofetil for
myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology
2003;61:1438-40.
24. Meriggioli MN, Sanders DB. Myasthenia gravis: diagnosis. Semin Neurol
2004;24:31-9.
26. Oh SJ, Kim DE, Kuruoglu R, Bradley RJ, Dwyer D. Diagnostic sensitivity of the
laboratory tests in myasthenia gravis. Muscle Nerve 1992;15:720-4.
28. Phillips LH. The epidemiology of myasthenia gravis. Semin Neurol 2004;24:17-20.
29. Phillips LH,2nd, Torner JC. Epidemiologic evidence for a changing natural history of
myasthenia gravis. Neurology 1996;47:1233-8.
30. Pinching AJ, Peters DK. Remission of myasthenia gravis following plasma-exchange.
Lancet 1976;2:1373-6.
31. Poulas K, Tsibri E, Papanastasiou D, et al. Equal male and female incidence of
myasthenia gravis. Neurology 2000;54:1202-3.
32. Ricny J, Simkova L, Vincent A. Determination of anti-acetylcholine receptor
antibodies in myasthenic patients by use of time-resolved fluorescence. Clin Chem
2002;48:549-54.
33. Rowland LP. Controversies about the treatment of myasthenia gravis. Journal of
Neurology, Neurosurgery & Psychiatry 1980;43:644-59.
34. Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR. Corticosteroids for myasthenia
gravis. Cochrane Database Syst Rev 2005;:002828.
38. Thomas CE, Mayer SA, Gungor Y, et al. Myasthenic crisis: clinical features,
mortality, complications, and risk factors for prolonged intubation. Neurology
1997;48:1253-60.
39. Toyka KV, Brachman DB, Pestronk A, Kao I. Myasthenia gravis: passive transfer
from man to mouse. Science 1975;190:397-9.
41. Vincent A, McConville J, Farrugia ME, et al. Antibodies in myasthenia gravis and
related disorders. Ann N Y Acad Sci 2003;998:324-35.
42. Wittbrodt ET. Drugs and myasthenia gravis. An update. Arch Intern Med
1997;157:399-408.
43. Yi Q, Pirskanen R, Lefvert AK. Human muscle acetylcholine receptor reactive T and
B lymphocytes in the peripheral blood of patients with myasthenia gravis. J
Neuroimmunol 1993;42:215-22.
47. Merritt's Neurology 10th Ed. (June 2000): by H. Houston Textbook of Neurology
Merritt (Ed), Lewis P. Rowland (Ed), Randy Rowland. Lippincott Williams & Wilkins
Publishers